ABSTRACT: Cysteine oxidative modification of cellular proteins is crucial for many aspects of cardiac hypertrophy development. However, integrated dissection of multiple types of cysteine oxidative post-translational modifications (O-PTM) of proteomes in cardiac hypertrophy is currently missing. Here we developed a novel discovery platform that encompasses a customized biotin switch-based quantitative proteomics pipeline and an advanced analytic workflow to comprehensively profile the landscape of cysteine O-PTM in an ISO-induced cardiac hypertrophy mouse model. Specifically, we identified a total of 1655 proteins containing 3324 oxidized cysteine sites by at least one of the following three modifications: reversible cysteine O-PTM, cysteine sulfinylation (CysSO 2 H), and cysteine sulfonylation (CysSO 3 H). Analyzing the hypertrophy signatures that are reproducibly discovered from this computational workflow unveiled four biological processes with increased cysteine O-PTM. Among them, protein phosphorylation, creatine metabolism, and response to elevated Ca 2+ pathways exhibited an elevation of cysteine O-PTM in early stages, whereas glucose metabolism enzymes were increasingly modified in later stages, illustrating a temporal regulatory map in cardiac hypertrophy. Our cysteine O-PTM platform depicts a dynamic and integrated landscape of the cysteine oxidative proteome, through the extracted molecular signatures, and provides critical mechanistic insights in cardiac hypertrophy. Data are available via ProteomeXchange with identifier PXD010336.
■ INTRODUCTION
Cardiac hypertrophy is an adaptive response of the heart to pressure overload and a risk factor for heart failure and sudden cardiac death. 1−3 The complex and dynamic pathophysiological mechanisms surrounding cardiac hypertrophy have been the focus of many investigations seeking therapeutic strategies. Reactive oxygen and nitrogen species (RO/NS) have been recognized as second messengers that mediate important biological processes during the development of cardiac hypertrophy. 2, 4 As a major target of RO/NS, protein cysteine residues can act as molecular switches and undergo various types of oxidative post-translational modifications (O-PTM), 5 which can alter protein 3D structure and activity in cellular signaling, adaptive and maladaptive cardiac responses. 4, 6, 7 Major cysteine O-PTM types observed in cardiac muscle include reversible (S-nitrosylation, S-glutathionylation, sulfenic acid, inter-and intramolecular disulfide bonds, and Ssulfhydration) and irreversible sulfinic acid (CysSO 2 H) or sulfonic acid (CysSO 3 H) modifications. 4, 8, 9 As dysregulation of cysteine O-PTM is directly associated with disease pathology, 4, 10 identification and characterization of cysteine O-PTM could yield a wider range of biomarkers and therapeutic targets for diseases characterized by oxidative stress. Because of the complexity of the cysteine oxidative proteome, elucidation of these molecular signatures during hypertrophy progression is currently lacking. Biotin switch assays and numerous iterations of this technique provide validated toolkits to customize the proteomic discovery platform and maximize the detection and quantification of the labile reversible cysteine O-PTM. 4, 11 For example, work by Jennifer van Eyk's laboratory has advanced methodologies to specifically detect S-nitrosylation and measure individual protein thiol-reactivity, thereby discriminating artifacts and ambiguity surrounding site assignment of oxidation. 12, 13 Meanwhile, spline-based computational analysis enables extraction of temporal patterns.
14, 15 Here, we present the first proteome-wide study of major cysteine modification types in cardiac hypertrophy including reversible O-PTM, CysSO 2 H, and CysSO 3 H. We devised a biotin switch-based cysteine O-PTM discovery platform specific for multitime-point quantitative proteomic analysis at different disease stages of hypertrophic progression. To limit nonbiologically oxidized peptides, we selected a maleimide-based reagent for enrichment labeling and combined dimethyl labeling for quantification. Compared to IAM based labeling, maleimide provides higher specificity and reactivity with free thiols. 16, 17 In addition, dimethyl based quantitative labeling is highly efficient and cost-effective in studies with large sample size. We implemented the cubic spline-based computational workflow to capture the cysteine O-PTM clusters with distinct temporal profiles and with high association with hypertrophy phenotypic temporal profile. We define proteins in these clusters as molecular signatures. The novelty lies in this being the first study to link global oxidative proteomic signatures to distinct time points of hypertrophic progression, thus showcasing these temporal fingerprints rather than a singular protein or snapshot at a specific time point.
■ METHODS AND MATERIALS Experimental Animal Models
Male C57BL/6J mice, 9−12 weeks of age (Jackson Laboratories), were housed in a 12-h light/12-h dark cycle with controlled temperature, humidity, and access to standard chow and water ad libitum. Mice were surgically implanted with a subcutaneous micro-osmotic pump (ALZET) delivering 15 mg/kg/day isoproterenol (ISO) (Sigma) or saline vehicle. 18, 19 In this treatment protocol, mice developed a gradual cardiac hypertrophy phenotype characterized by significantly increased ejection fraction and HW/BW. 19, 20 Independent groups of three mice from each treatment condition were euthanized for sample collection at 1, 3, 5, 7, 10, and 14 days postimplantation. Four technical replicates were performed for each treatment condition. All animal procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals by the National Research Council and approved by the Animal Research Committee at UCLA.
Biotin Switch-Based Sample Processing
Protein Extraction. Left ventricles were collected from mouse hearts and placed in 1 mL NP-40 lysis buffer (50 mM Tris−HCl, pH 8, 137 mM NaCl, 10% glycerol, 1% NP-40, 2 mM EDTA) containing 100 mM N-ethylmaleimide (NEM) and Halt Protease Inhibitor Cocktail (100X) (ThermoFisher Scientific). Tissue was homogenized using a glass hand homogenizer and mixed by rotation for 2 h at 4°C before centrifugation at 13 800g for 20 min at 4°C. The protein concentration of the supernatant was measured using the DC protein assay (Bio-Rad).
Biotin Switch-Based Labeling of Reversible Cysteine O-PTM. Aliquots containing 2 mg protein were prepared, then precipitated by 10% trichloroacetic acid (TCA) and centrifuged at 20 000g for 15 min at 4°C. One wash with ice-cold 5% TCA and two washes with 95% ethanol were performed to get rid of small molecules. Pellets were resuspended and alkylated in 1 mL of urea-containing cysteine modification buffer (CMBU) (0.1 M HEPES-NaOH, pH7.4, 1% SDS, 10 mM diethylenetriaminepentaacetic acid [DTPA], 6 M urea) with 0.1 M NEM. After 30 min rotation at room temperature, the samples were reduced by 0.12 M dithiothreitol (DTT) and rotated for another 60 min. To quantify the total abundance of cysteine sites and to preserve cysteine sulfinylation (CysSO 2 H) and sulfonylation (CysSO 3 H), 10% of the lysate was reserved as an unlabeled portion and underwent acetone precipitation followed by digestion. For the remaining 90%, proteins were separated from small molecules by centrifugation with 10% TCA, followed by one wash with 5% TCA and two washes with 95% ethanol. Pellets were suspended in 300 μL of CMBU with 0.1 mM maleimide-biotin (Mal-Biotin) (Sigma-Aldrich). After a 30 min rotation at room temperature, unreacted NEM was quenched with 10 mM DTT for an additional 30 min. Small molecules and proteins were separated by TCA and ethanol washes as described above. 21, 22 Digestion and Dimethyl Labeling. Pellets from both labeled and unlabeled portions were solubilized in 0.1 M triethylammonium bicarbonate buffer (TAEB) with 0.1% Rapigest (Waters) and heated at 60°C for 45 min. Solubilized proteins were alkylated with 9 mM iodoacetamide (IAM) incubation in the dark at room temperature for 30 min. The alkylated lysate underwent trypsin digestion overnight (16 h) at 37°C with a 1:100 ratio of trypsin to protein. A final concentration of 0.16% (vol/vol) CH 2 O or C 2 H 2 O (SigmaAldrich) and 24 mM sodium cyanoborohydride (NaBH 3 CN) (Sigma-Aldrich) were added to the designated samples with light or medium labeling, respectively. Reciprocal labeling was performed on two out of four technical replicates to minimize the technical bias from dimethyl labeling. After a 1 h incubation at room temperature, 0.16% (vol/vol) ammonium solution was added and mixed for 15 min to quench the reaction.
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Mal-Biotin Enrichment. Mal-biotin and dimethyl labeled peptides were diluted in 1.2 mL of PBS with 200 μL of prewashed High-Capacity NeutrAvidin slurry (Thermo Scientific). After overnight incubation, the sample was centrifuged, washed twice with 1 mL of PBS, once with 50 mM ammonium bicarbonate with 20% methanol, and eluted with 50% Pierce acetonitrile (ACN) with 0.4% trifluoroacetic acid (TFA).
26
C18 Column Cleanup. All samples were subjected to 30 min incubation at 37°C with 1% TFA and centrifugation (13 000g for 15 min) to remove remaining Rapigest. Samples were cleaned with Pierce C18 Spin Columns (Thermo Scientific) to remove any interfering substances prior to liquid chromatography−tandem mass spectrometry (LC−MS/MS) analysis.
LC−MS/MS Analysis
LC−MS/MS was performed on digested peptides as done previously. 18, 19 To reduce sample complexity and increase protein coverage, we fractionated peptide samples using highpH/low−pH two-dimensional reversed-phase chromatography prior to MS/MS. Fifty micrograms of peptides was injected into a Phenomenex C18 column (Jupiter Proteo C12, 4-μm particle, 90-Å pore, 100 mm × 1 mm dimension) using a Finnigan Surveyor LC system (Thermo Scientific) for the firstdimension (high-pH) separation. We established a gradient between solvent A (20 mM ammonium formate, pH 10) and solvent B (20 mM ammonium formate, 90% acetonitrile, pH10) at a 50 μL min −1 flow-rate with the following timing and solvent proportions: 0−5% solvent B in solvent A from 0− 2 min; 5−35% solvent B in solvent A from 3−32 min; and, finally, 80% solvent B in solvent A from 32−37 min. Six fractions of peptides were collected from 16−40 min, lyophilized, and redissolved in 20 μL of 0.5% formic acid with 2% acetonitrile. Each high-pH fraction was injected (10 μL) to an EasySpray C18 column (PepMap, 3-μm particle, 100-Å pore; 75 μm × 150 mm dimension; Thermo Scientific) using an autosampler on a single Easy-nLC 1000 nano-UPLC system (Thermo Scientific) for second-dimension (low-pH) reversed-phase chromatography analysis. We established a gradient between solvent A (0.1% formic acid, 2% acetonitrile) and solvent B (0.1% formic acid, 80% acetonitrile) at a flow rate of 300 nL min −1 with the following timing and solvent proportions: 0−40% solvent B from 0−110 min; 40−80% B from 110−117 min; and 80% B from 117−120 min. Column pressure was maintained below 150 bar. High-resolution LC− MS/MS was performed on a single LTQ Orbitrap Elite instrument (Thermo Scientific) through a Thermo EasySpray interface. MS signals were acquired in Fourier-Transform/IonTrap (FT/IT) mode: each FT MS1 survey scan was analyzed at 400 to 2000 m/z mass range and 60 000 resolving power in profile mode, followed by rapid IT MS2 scans on the top 15 ions with monoisotopic peak selection and 3000 intensity threshold. MS2 precursor isolation width was set to 2 m/z, normalized collision energy was 35, and charge state 1 and unassigned charge state were excluded. MS1 and MS2 target ion accumulation targets were 10 4 and 10 6 , respectively. MS1 lock mass (m/z 425.120025) and dynamic exclusion (90 s) were used. Throughout the LC−MS/MS experiment, column temperature was held at a constant 50°C.
Quantification of Cysteine O-PTM Abundance
The acquired raw mass spectra were processed with MaxQuant software 27 version 1.5.6.0 as described. 23 Peptide identification was performed using the Andromeda search engine, 28 against a reverse-decoyed protein sequence database (UniProt Reference Proteome, reviewed, accessed June 12, 2016) . This Mus musculus proteome (taxonomy ID: 10090) database contains 33 588 canonical sequences and does not include isoform information. Common contaminants were included in the database search. First and main searches were performed with precursor mass tolerances of 20 and 4.5 ppm. Product ion tolerance was set to 0.5 Da. Specificity for trypsin cleavage was required, allowing up to two missed cleavage sites.
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Dimethylated peptide labels were identified using the "multiplicity" query, including "DimethLys0" and "DimethN-term0" as light labels as well as "DimethLys4" and "DimethN4" as medium labels with a maximum four modified sites for each identified peptide. Peptide ions from up to three isotopic peaks with fragment mass tolerance of 600 ppm were allowed. Protein inference required ≤5% peptide spectra matching (PSM), posterior error probability (PEP), and ≤1% global level protein false discovery rate (FDR) (Q-value ≤1%), as well as a minimum of two ratio counts. Peptides with a cysteine count lower than one were excluded, along with reverse and potential contaminant flagged peptides. Modified peptide identifications with an Andromeda search score greater than 40, a delta score greater than 6, and a localization probability >0.8 were allowed. 30 All searches for a given data set were based on one set of Andromeda peak list files (apl-files). Each of the cysteine modifications (i.e., Malbiotin, NEM, IAM, CysSO 2 H, and CysSO 3 H) was generated as a separate output file with identified cysteine sites, their extracted ion chromatogram (XIC) values, and normalized ratios of ISO versus vehicle conditions calculated from the differential dimethyl labeled peptides. To ensure data quality, technical replicates with significant change (p-value <0.05) in overall normalized ratio distribution among all four replicates were excluded. The total abundance of one cysteine site is quantified as the sum of XIC values from both modified and unmodified forms of that particular cysteine. Detailed information on number of spectra for identification and quantification, as well as number of unique peptide identified per experimental group are listed in Supplemental Table S Cubic Spline-Based Temporal Clustering. Mal-biotin labeled cysteine sites or total cysteine sites with abundance values for at least four out of six time points in both ISO and vehicle groups were selected for cubic spline-based temporal clustering. The averaged ratio of abundance in ISO to vehicle across replicates was calculated per site. Missing abundance values for a modification site were imputed using average abundance of remaining time-points. After scaling and centering, cubic splines were fitted to ratios across the time points in the R statistical programming language (v3.4.3). The predicted abundance ratios from cubic spline were used for Kmean clustering (kmean package in R) following identification of the cluster numbers (mclust package in R). All the codes used for the analyses were deposited to the Github public repository (https://github.com/UCLA-BD2K/Cubic-Splinebased-Temporal-Analysis-Workflow).
Additional Statistical Analysis. The significance of abundance change in ISO and vehicle conditions was evaluated by a paired two-sided t test.
Pearson correlation was performed to analyze the association between phenotype and abundance of Mal-biotin labeled cysteines.
Functional Annotations. Cellular pathway information was retrieved from Reactome (release v63, 2017_12) (https:// reactome.org/). 33 To exclude single entity function and nonspecific/generalized pathway terms (e.g., metabolism), enriched pathways are required to house a minimum of two found entities and a maximum of 200 total entities. Significantly enriched pathways are defined by FDR < 0.05 calculated from Fisher's exact test with FDR multiple test correction. neXtProt (release 2018−02) was implemented to annotate the biological processes and disease association of key proteins identified in the analysis.
■ RESULTS AND DISCUSSION

Overview
We developed a cysteine O-PTM discovery platform by integrating a biotin switch-based quantitative proteomics approach with advanced computational analysis, and we applied the novel platform on an ISO-induced cardiac hypertrophic mouse model. First, we defined the abundance distribution of three types of cysteine O-PTM, including reversible O-PTM, CysSO 2 H, and CysSO 3 H during the progression of hypertrophy. Second, we applied statistical analysis to identify key proteins with significantly increased or decreased cysteine O-PTM abundance, followed by cubic spline-based K-mean clustering to dissect the temporal profiles of cysteine O-PTM together with their total cysteine abundance. Third, temporal signatures along with their enriched hypertrophic pathways were identified. Finally, we Figure 1 . Quantitative cysteine O-PTM proteomics workflow. Left ventricular tissue samples originated from C57BL/6J were subjected to ISO conditions or saline vehicle (vehicle) for 1, 3, 5, 7, 10, and 14 days, with n = 3 mice per group. Extracted proteins underwent biotin switch for reversible cysteine O-PTM labeling. First, free cysteines in the cell lysate were alkylated with NEM to prevent nonspecific labeling of reversible cysteine O-PTM. Subsequently, reversibly oxidized cysteine were reduced with DTT. At this point, 10% of the lysate was separated out for the quantification of the total cysteine sites abundance and DTT-irreversible cysteine O-PTMs (i.e., CysSO 2 H and CysSO 3 H) (right side of flowchart). The remaining 90% (left side of flowchart) was treated with mal-biotin, which labels newly reduced, free cysteine residues. Following trypsin digestion and IAM alkylation of newly exposed free cysteines, lysates from Normal and Hypertrophy groups were differentially labeled with medium/light dimethyl in two of the four technical replicates, whereas the other two received reciprocol labeling. The dimethyl-labeled peptides were quenched by ammonium and equally mixed. established the association between cysteine O-PTM profiles and hypertrophic phenotypes, keying in on cysteine sites that were significantly correlated with the phenotype dynamics. Integrated analysis of key sites extracted from our computational approaches was performed to comprehensively identify molecular signatures and provide mechanistic insights during the development of cardiac hypertrophy.
Impact of ISO-Induced Hypertrophy on Cysteine O-PTM
Using our cysteine O-PTM discovery pipeline on mouse LV tissue from ISO and vehicle groups (Figure 1 ), we identified a total of 2505 proteins containing 6818 cysteine sites; with 1655 proteins containing 3324 sites modified by at least one of three cysteine O-PTM types. Specifically, 1095 proteins containing 2162 sites, 484 proteins containing 671 sites, and 447 proteins containing 613 sites were modified by reversible modification, CysSO 2 H, and CysSO 3 H, respectively. Among the reversibly modified proteins and cysteine sites, only 167 proteins containing 470 sites and 8 proteins containing 9 sites based on UniProt are known sites of disulfide-bonds and nitrosylated, respectively, revealing that the majority of identified cysteine sites are novel. Figure 2A illustrates the overall change in abundance distribution of reversible cysteine O-PTM over the progression of hypertrophy, with the average abundance of reversible cysteine O-PTM sites across four technical replicates for each time point plotted. All histograms exhibit a J-shaped curve, demonstrating the higher frequency of modified cysteine sites concentrated in the low abundance XIC range. Notably, the distribution of O-PTM abundance in ISO demonstrates a sizable reduction in the lower abundance range, indicating a global enrichment of O-PTM occurring as early as Day3. Figure 2B shows a Venn diagram to depict the number of proteins associated with each individual type of cysteine modification. To summarize, 1057 sites within 377 proteins are unique to an enriched reversible O-PTM proteome, demonstrating the advantage of using enrichment to concentrate less abundant but highly oxidized proteins. The overlapping cysteine sites among three modification types are limited (5 sites), suggesting that the type of cysteine O-PTM is highly site-specific. Comparatively, the numbers of proteins comodified with all three modification types are significantly higher, suggesting that diverse cysteine O-PTM patterns occur on the same protein albeit in a site-specific manner. Overall, these data indicate that the oxidative regulation of proteins requires complex orchestration of myriad oxidative chemistries in a sitespecific manner.
We mapped the distribution of O-PTM abundance, expressed as a ratio of ISO over vehicle across six time points in violin plots for the three modification types ( Figure 2C ). Consistent with 2A, the ratio means of reversible O-PTM on Day 3, 5, 10, and 14 in ISO over vehicle are slightly above zero, demonstrating an increase in reversible O-PTM abundance. CysSO 2 H oxidized sites exhibit no distribution change, whereas CysSO 3 H oxidized sites have upshifts on Day 5 and 14. The distinct patterns of abundance distribution among the three modification types indicate O-PTM type-specific proteomic regulation during ISO-induced hypertrophy and oxidative stress.
To identify sites of cysteine O-PTM that are significantly altered by ISO treatment, we applied a t test on the log 2 -transformed fold-change of the reversible cysteine O-PTM (ISO/vehicle) with at least three time points, where a p-value < 0.05 and fold-change within the top or bottom 20th Figure 2D , top panel), we found 128 sites within 74 proteins with significantly increased abundance and 46 sites within 39 proteins with significantly decreased abundance during ISO treatment, marking their potential to be signatures of cardiac hypertrophy. In addition, one and two CysSO 3 H oxidized sites are significantly increased and decreased, respectively ( Figure 2D, lower panel) .
Reactome identified 17 and 55 pathways that are enriched by proteins with significantly increased and decreased reversible cysteine sites, respectively ( Figure 2D, top panel) . Specifically, proteins with significantly decreased reversibly oxidized sites are significantly enriched in three extracellular matrix organization and signaling pathways, two ion homeostasis and transportation pathways, and two TCA cycle and respiratory electron transport (TCA) pathway. Proteins with significantly increased reversibly oxidized cysteine sites are significantly enriched in seven transcriptional and translational regulation, two post-translational modification (PTM) of protein, two glucose metabolism, and three TCA cycle and respiratory electron transport pathways. Notably, the "TCA cycle and respiratory electron transport" pathway is enriched in both significantly increased and decreased sites with associated proteins are labeled by their UniProt ID. This observation reveals a significant and diverse reversible O-PTM regulation on mitochondrial metabolism during ISO-induced cardiac hypertrophy. In addition, significantly increased cysteine modification on protein susceptible to methylation and phosphorylation indicates further hierarchical interactions between PTMs. Zinc finger factor, ZEP1 is significantly decreased in CysSO 3 H (associated proteins are labeled by their UniProt ID), demonstrating redox regulation of transcriptional regulation during hypertrophy. Detailed information on featured sites, proteins, and their enriched pathways are listed in Supplemental Tables S-1 and S-2, respectively.
Integrated Temporal Profiles of Cysteine O-PTM in Hypertrophic Heart Proteome
To characterize the dynamic patterns of reversible cysteine O-PTM during the progression of cardiac hypertrophy, we calculated the abundance ratios of each reversible cysteine O-PTM site in ISO over vehicle for 1, 3, 5, 7, 10, and 14 days and employed a cubic spline-based smoothing approach for data denoising. The cubic spline-fitted data were subsequently classified by K-means clustering to produce a total of eight unique dynamic patterns ( Figure 3A ). The largest cluster (Cluster 6, n = 198) remains unchanged during ISO treatment. These likely represent structural disulfide cysteines of housekeeping proteins. Consistent with this notion, reactome analysis identified extracellular matrix (ECM) organization and signaling pathways to be enriched in this cluster, and ECM proteins are known to be rich in structural disulfide bonds.
The dynamic patterns of eight clusters were represented in the stripcharts with smoothing lines, demonstrating the temporal feature of each cluster ( Figure 3B ). Different temporal patterns of reversible O-PTM clusters may reveal the hidden association between dynamic regulation of biological processes and the progression of cardiac hypertrophy. We applied determination coefficient analysis to extract key sites as temporal signatures that are highly correlated (R 2 > 0.8) with the temporal feature of their corresponding clusters. Cluster 6, with its lack of significant temporal changes to cysteine sites, is excluded from temporal signatures analysis. Among a total of 415 sites within 250 proteins that match the criteria as temporal signatures, the majority (404 sites within 243 proteins) are modified by reversible cysteine O-PTM, whereas five sites within four proteins by CysSO 2 H and six sites within five proteins by CysSO 3 H. Notably, majority of CysSO 2 H sites (3 out of 5) are distributed in Cluster 1, exhibiting a continual decrease whereas the majority of CysSO 3 H sites (5 out of 6) are enriched in Cluster 7, exhibiting a continual increase. Notably, CysSO 2 H can be enzymatically reduced to free cysteine and can also be further oxidized into CysSO 3 H, which is nonreducible. 35, 36 These observations revealed distinct regulation pattern of different irreversible modification types during ISO-induced oxidative stress. Specifically, CysSO 2 H on Cys164 and CysSO 3 H on Cys167 in ATP7b (Q64446) shared the temporal pattern of continual increase (Cluster 7), suggesting an inactivation of ATP7b during cardiac hypertrophy. As a malfunction in ATP7b leads to cellular copper accumulation and cardiomyopathy in Wilson disease, 37 the mapping of ATP7b's irreversible O-PTM temporal pattern offers mechanistic insights into cardiac complications of Wilson disease.
In a total of 243 reversibly oxidized proteins, 62 out of 90 bore at least two sites that fall into more than one temporal cluster. The distinct temporal regulation of cysteine sites within the same protein is possibly due to the unique microenvironment of the particular cysteine sites (e.g., cysteine F pK a , enzymatic interaction). We utilized Reactome to perform pathway enrichment with temporal signature proteins that are unique to one cluster. Cluster 1 is characterized by a continual decrease and significantly enriched in branched-chain amino acid (BCAA) catabolism, fatty acid beta-oxidation (FABO), and TCA pathways; Cluster 2 by an initial decrease that dips on Day 7 and significantly enriched in BCAA and TCA pathways; Cluster 3 by a sharply increase after Day 7 and significantly enriched in BCAA, TCA, and glucose metabolism; Cluster 4 by a sinusoidal curve and significantly enriched in protein phosphorylation and complement cascade; Cluster 5 by an arched curve that peaks on Day 7 and significantly enriched in protein phosphorylation and creatine metabolism; Cluster 6 by no change and significantly enriched in extracellular matrix organization and signaling; and Cluster 7 by a continual increase and significantly enriched in BCAA, FABO, TCA, glucose metabolism, and creatine metabolism; and Cluster 8 by an initial sharp decrease before returning to baseline levels. Reversible cysteine O-PTM sites/proteins with significant alteration in abundance ratio across 14 days after ISO were widely distributed among eight clusters, suggesting that dynamic temporal patterns is a state-of-the-art measurement and prediction that is independent of the absolute value of end-point measurements. Specifically, three 40S ribosomal proteins, S3, S6, and S11, with significantly increased oxidation abundance are enriched in Cluster 1 (continual decrease), suggesting an initial wave of sharply increased oxidation in response to ISO treatment that diminishes as the heart hypertrophies. Notably, the majority of glucose metabolism proteins (4 out of 5) with significantly increased abundance belong to Cluster 7, demonstrating a strong and significant increase of reversible cysteine O-PTM in glucose metabolism during cardiac hypertrophy. In addition, the conserved Cys17 in the ATPase domain of the cytosolic chaperone protein, Hspa8, was continually oxidized (Cluster 7). As the perpetual oxidation of the conserved cysteine in the ER chaperone, Hspa5, has been shown to enhance chaperone function and ER homeostasis, the perpetual oxidation of Hspa8 indicates a potential function in cytosolic protein homeostasis during ISOinduced cardiac hypertrophy. 21, 22, 38 The stoichiometry is an important feature of PTM and can be calculated by comparing the abundance of a modified form with all forms of a site of interest. Integrating the temporal patterns of total cysteine abundance and reversible cysteine O-PTM further reveals the comprehensive regulation of cysteine O-PTM stoichiometry. We applied cubic spline based clustering on total cysteine abundance and subsequently coclustered temporal patterns of reversible cysteine O-PTM with total cysteine abundance ( Figure 4) . Briefly, cubic splinebased K-mean clustering was implemented to determine the temporal clusters of the total cysteine proteome. Subsequently, temporal signature sites of total cysteines from each cluster were extracted by determination coefficient analysis with R 2 > 0.8 as described and combined with the temporal pattern of oxidized cysteine sites. Clusters with more than three sites Ten coclusters with more than three cysteine sites were identified and demonstrated in the stripcharts, exhibiting the trends in the normalized abundance ratio of reversible cysteine O-PTM and total cysteine sites (y-axis) over six time points (x-axis). As previously described, Cluster 1 of reversible cysteine O-PTM sites is characterized by continual decrease; Cluster 3 by a sharp increase after Day7; Cluster 5 by an arched curve that peaks on Day 7; Cluster 6 by no change; and Cluster 7 by continual increase. Cluster A of total cysteine sites is characterized by continual increase; Cluster B by no change; Cluster C by continual decrease; Cluster D by initial sharp decrease that dips between Day 7−10; Cluster E by an arched curve that peaks on Day 7. Key pathways are listed on the stripcharts of their corresponding clusters. Detailed information regarding proteins of each cluster and their enriched pathways is listed in the Supplemental Tables S-3 were considered as conserved patterns and included in the subsequent analysis. Figure 4 shows a total of 10 coclusters with more than three sites were identified. These coclusters consist of three temporal patterns from reversible and irreversible cysteine modification identified previously and four newly identified temporal patterns from total cysteine abundance. Cluster 1A is characterized by continual decrease in oxidation with continual increase in total abundance, suggesting a decrease in oxidation occupancy, Cluster 1B by continual decreased oxidation with no change in total abundance and enriched in fatty acid metabolism, Cluster 1C by continual decrease in both oxidation and total abundance and enriched in branched chain amino acid catabolism, Cluster 1D by continual decreased oxidation with initial decreased abundance that dips on Day 7 and enriched in respiratory electron transport, Cluster 7A by both continual increase in oxidation and total abundance and enriched in glucose metabolism, FABO, and lipoprotein remodeling, Cluster 7B by continual increased oxidation with no change in total abundance and enriched in glucose metabolism and ATP synthesis, Cluster 7C by continual increased oxidation with decreased total abundance and enriched in retinoic acid signaling, suggesting a continual increase in cysteine O-PTM occupancy in regulating retinoic acid, which contributes to cardiac development, Cluster 7E by continual increase oxidation with arched curve that peaks on Day 7, Cluster 3A by initial decreased oxidation that dips on Day 7 with continual increased total abundance and enriched in pyruvate metabolism and TCA cycle, and Cluster 5B by an arched curve that peaks on Day 7 with no change in total abundance. In addition to sites modified by reversible O-PTM, two CysSO 3 H sites bore the temporal pattern of Cluster 7A. Notably, three major enriched pathways from Cluster1, BCAA, FABO, and TCA, were divided into Cluster 1B, 1C, and 1D, according to the temporal patterns of their total cysteine abundance, demonstrating the clustering of their temporal pattern is dependent on their biological function. Among clusters with altered stoichiometry during cardiac hypertrophy, Cluster 1B and Cluster 7B are enriched in FABO and glucose metabolism, respectively. As cardiac hypertrophy is featured by an increased reliance on glucose with an overall reduced fatty acid metabolism, 39 these observations provide a detailed molecular map that reveals an additional layer of regulation in mitochondrial energy metabolism via reversible cysteine O-PTM. Detailed information on featured sites, proteins, and Tables S-5 and S-6, respectively. Abbreviations: isoproterenol (ISO); heart weight-body weight ratio (HW/BW); control (CTRL). Temporal cluster analysis revealed the intrinsic temporal regulation of a cysteine O-PTM site, which may contribute to or respond to the dynamic pattern of the cardiac hypertrophy phenotype. The heart weight−body weight (HW/BW) ratios of the mouse strain were documented along with the left ventricle sample collections to provide temporal phenotypic profiles. During ISO treatment, all mouse strains exhibited cardiac hypertrophy development starting from Day 1 post ISO-treatment ( Figure 5A ). The averaged ratio of HW/BW across six time points increased 20% in ISO over vehicle. Interestingly, we observed an arched curve of hypertrophy development that peaked on Day 5 (33% higher than control) and stabilized on Day 10 (∼14% higher than control). This is consistent with previous observations of the ISO mouse model in C57BL/6J. 40 To directly map the association between temporal change of cysteine O-PTM and that of the hypertrophy phenotype, we performed cubic spline-based Pearson correlation. We selected 29 cysteine O-PTM sites with a p-value < 0.01 as key oxidation sites that significantly associated with cardiac hypertrophy. Among them, 18 cysteine sites within 17 proteins and 11 cysteine sites within 10 proteins were positively and negatively correlated with HW/BW changes, respectively ( Figure 5B ). Pathway enrichment of proteins with a positive correlation to phenotype unveiled four secretory proteins in the extracellular space that regulate Insulin-like Growth Factor (IGF) transport, a key regulatory mechanism of cardiac hypertrophy. 41, 42 In addition, a BCAA pathway protein, MCCC2, was identified in both correlation groups, demonstrating a diverse regulation of MCCC2 cysteine O-PTM. Notably, reversible O-PTM of an additional two key BCAA proteins, BCAT2 and DBT, were observed in Cluster 1C, featured by continually decreased oxidation and total cysteine abundance. As a BCAA catabolic defect is a metabolic hallmark of the failing heart, 43 diverse oxidative regulation of BCAA proteins can potentially contribute to hypertrophy by metabolic reprogramming. Detailed information on featured sites, proteins, and their enriched pathways are listed in Supplemental Tables S-5 and S-6, respectively.
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Signature Pathways and Proteins That Contribute to Cardiac Hypertrophy
Combining molecular signatures from differential analysis, cubic spline-based temporal clustering, and phenotypic correlation, we highlighted seven biological processes that are reproducibly identified as signature pathways during cardiac hypertrophy, including TCA, FABO, BCAA, glucose metabolism, protein phosphorylation, creatine metabolism, and response to elevated Ca 2+ . Specifically, among pathways enriched in proteins with significantly increased reversible modification, protein phosphorylation, creatine metabolism, and response to elevated Ca 2+ pathways exhibited an increase in cysteine modification in early stages of hypertrophy, whereas glucose metabolism pathways were modified in the later stages ( Figure 6A) . Comparatively, the cysteine oxidative profiles of TCA, FABO, and BCAA were more complicated, as metabolic reprogramming is a highly integrative process with complex compensatory mechanisms. We mapped all identified BCAA pathway proteins and their corresponding temporal dynamics. As expected, temporal trends of cysteine modification differ across pathways and even among cysteine sites within one protein. Interestingly, cysteine temporal profiles of valine catabolism subpathways exhibit a trend toward increase, whereas that of leucine and isoleucine catabolism uniformly illustrates a decreased trend at early stage of hypertrophy. These observations demonstrate that cysteine O-PTM profiles are highly correlated with key biological processes during cardiac hypertrophy. Furthermore, these integrated molecular signatures of hypertrophy are novel and can be used to define phenotypes of metabolic reprogramming in new and informative ways.
Role of Cysteine O-PTM in Cardiovascular Biology
ISO induced beta-adrenoceptor stimulation has been shown to evoke cardiac oxidative stress. 44, 45 Specifically, this process is mediated through increased mitochondrial ROS production, as mitochondrial targeted antioxidant diminish oxidative stress and its downstream biological events. 46 Meanwhile, the capacity of nitric oxide synthesis is also increased in response ISO, likely from enhanced expression of endothelial and inducible nitric oxide synthases. 47 During heart failure development, elevated RO/NS production in turn leads to modification of reactive cysteine thiol groups. The highly reactive thiol group of cysteine residues has made it difficult to isolate native versus nonbiological oxidized peptides in the cardiovascular system, and subsequently, to elucidate their biological role. Pioneering studies on both technological and biological fronts have overcome this barrier and broken new ground in cardiovascular medicine. Recent work from Jennifer van Eyk's laboratory identified distinct subpopulations of nitrosylated cysteines through a dual-labeling of nitrosylation that reduces labeling bias. 26 This advanced methodology was then utilized to explore glycogen synthase kinase 3β (GSK3β) regulation by nitrosylation and it was discovered that nitrosylation reduces GSK3β kinase activity and promotes its nuclear translocation. 48 The biological and physiological roles of cysteine O-PTM in both vascular systems and cardiac muscle have been pioneered and carried into clinical translation by the work of Jonathan Stamler and Elizabeth Murphy, respectively. A seminal paper in 2004 by the Stamler laboratory was the first demonstration of a role of nitrosylation in innate immunity and vascular function. 49 Mice devoid of S-nitrosoglutathione reductase showed marked increased in nitrosylation, vascular damage, and mortality following endotoxic challenge. More recent work unveiled a role for the hemoglobin β Cys93 residue in nitrosylation-based vasoactivity, demonstrating that S-nitrosohemoglobin plays a role in cardioprotection. 50 This and other notable contributions 51−53 have revolutionized our understanding of cysteine O-PTM in vascular signaling. Figure 6 . continued among BCAA pathways exhibit diverse temporal trend. Notably, valine catabolism pathway exhibits an increased trend of cysteine modification whereas the temporal trend of leucine and isoleucine is decreased at early stage of hypertrophy. These observations suggest that oxidative cysteine regulation of BCAA pathway is highly compartmentalized by biological function. Abbreviations: branched-chain amino acid catabolism (BCAA).
Studies from Elizabeth Murphy's lab have advanced knowledge of cysteine O-PTM in cardiac muscle biology. This group pioneered novel labeling approaches for measuring nitrosylation occupancy, the fraction of a given protein that is nitrosylation modified in the myocardium, and demonstrated that nitrosylation occupancy levels following ischemic preconditioning protect against cysteine O-PTM. 54 More recent, formative work by this lab demonstrated increased nitrosylation abundance at Cys144 of the cardioprotective protein, TRIM72, is a molecular switch preventing TRIM72 degradation following an oxidative insult, which increases cardiomyocyte survival. 55 Other work unveiled complex profiles of nitroso-redox signaling and nitrosylation of cardiac proteins in failing versus nonfailing human cardiac tissue. Sexspecific differences in S-glutathionylation of endothelial nitric oxide synthase were discovered, adding to the overall complexity of these pathways in cardiac muscle. 56 Our measurements represent the sum of all types of cysteine O-PTM events including disulfide bonds, nitrosylation, glutathionylation, and irreversible cysteine O-PTMs. Among these modifications, different modifications result from diverse regulatory mechanisms 4 and modifications can be interconvertible. For example, glutathionylation of Cys63 on the ER stress protein BiP is mediated by sulfenylation. 21 Meanwhile, both sulfenylation and glutathionylation of BiP have been shown to enhance BiP's activity in preventing aggregation. Meanwhile, different modifications can also lead to distinct biological consequences. For example, two types of oxidative posttranslational modifications have been shown to occur on Cys674 of SERCA2: reversible S-glutathiolation increases SERCA activity, whereas irreversible oxidative CysSO 3 H is associated with decreased activity. 57 Conventionally, irreversible modifications were considered to be markers of cellular damage. Yet recently advances suggest that these modifications have regulatory capacities. For example, the unique active cysteine sites of nitrile hydratase and thiocyanate hydrolase are responsible for metal coordination and can be modified by CysSO 2 H. The fully reduced forms of these two enzymes appear inactive, suggesting that CysSO 2 H is critical in maintaining their catalytic activity. 58, 59 Our study provides key signatures modified by reversible and irreversible cysteine O-PTMs, facilitating the target prioritization for studying hierarchical regulation among different types of cysteine OPTMs.
Technical Considerations and Future Directions
Capitalizing on several modified variations of biotin switch method, 23, 60 we developed a quantitative approach for indepth characterization of the cysteine oxidized cardiac proteome. First, NEM alkylates free cysteines via a faster, more specific Michael addition reaction than the nucleophilic substitution reaction with IAM. 16, 17 Efficient labeling with less pH dependence makes NEM a great choice to preserve the labile reversible cysteine O-PTM and minimize artificial chemical alteration and nonspecific labeling during sample processing over IAM. Second, biotin maleimide labeling offers the efficiency and specificity accompanying the Michael addition reaction. In addition, as the avidin−biotin interaction is strong and rapid, 61 enrichment with high-capacity NeutrAvidin agarose enables a large-scale pull-down with high efficiency. Third, stable-isotope dimethyl labeling using reductive amination is a reliable widely used approach in MSbased quantitative proteomics. 25, 62 Specifically, dimethylation enhances fragmentation efficiency of collision-induced dissociation (CID) by increasing the number of positive charges on a peptide. 63 In addition, high cost-effectiveness makes dimethylation applicable for studies with any sample size.
Nevertheless, there are a few limitations to consider. The multistage process, including biotin maleimide labeling, dimethyl labeling, and avidin enrichment requires milligrams of starting material. The development of biotin maleimidebased isotope reagents would be a great tool to combine this two-stage labeling. While DTT is a potent and efficient reducing reagent for all types of reversible cysteine O-PTM, proteins with a large number of stable disulfide bonds will be prevalently enriched in this assay. On the other hand, this method can facilitate discovery of functional and catalytic disulfide bonds and less reactive cysteine O-PTMs that require more potent reductant. Despite the limitations mentioned above, our biotin switch-based reversible cysteine discovery platform provides a reliable workflow allowing robust detection of reversible cysteine sites at multiple time points during cardiac hypertrophy development.
To comprehensively understand the impact of ISO-induced hypertrophy on cysteine O-PTM sites and proteins identified from this robust biotin switch based quantitative proteomic approach, we used a bioinformatics approach that dissects the temporal pattern of the cysteine O-PTM proteome using a cubic spline-based K-mean clustering. 15, 64 The cubic spline method generates a fitted curve for all the cysteine O-PTM abundance values across time points for each oxidation site. This denoising method extracts the most fitted temporal pattern from a group of highly variable values with crossvalidation. The smoothed temporal curve facilitates the subsequent unsupervised clustering to accurately identify temporal clusters of interests. However, the assumption of this method is that alteration across time points is gradual and smooth; this will potentially have a trade-off with a sudden alteration between time points that is biologically significant. Thus, more time points are required or multiple temporal analysis methods widely used in the genomics field, including advanced pattern extraction, 65 can be adapted and applied to reveal the true biological signal from the technical bias.
■ CONCLUSIONS
Utilizing a novel cysteine O-PTM discovery platform composed of customized redox proteomics and advanced computational analysis, we present the first proteome-wide study of multitype cysteine O-PTM on the well-known mouse model of ISO-induced cardiac hypertrophy. The novelty and strength of our study lie in our ability to cluster the temporal behavioral profiles of cysteine residues and visualize distinct patterns of change as well as how they correlate to the hypertrophic phenotype. The advanced computational and statistical platform enabled us to create a dynamic and integrated picture of the entire cysteine oxidative proteome, a molecular signature that can be used for in-depth profiling and defining of various health and diseased states.
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